

Have You or Someone You Know Been Diagnosed with Alzheimer's Disease?

Consider Participating in Athira's Clinical Trials

The clinical trials of ATH-1017 are evaluating if a new investigational drug is safe and effective in improving symptoms of mild to moderate Alzheimer's disease.

ATH-1017 is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function.

Who is Eligible?

You or someone you know may be eligible if you:

- ◆ Are between 55 and 85 years of age
 - ◆ Have been diagnosed with Alzheimer's disease
 - ◆ Have a reliable support person or caregiver who is willing to participate in study visits, report on daily activities and oversee or help you with taking ATH-1017
- ◆ Study participation and study drug are free to all participants
 - ◆ You may receive a stipend to compensate for time and effort for study participation including meals, travel, etc.



Talk to your doctor about participating in Athira's clinical trials of ATH-1017

To learn more and find a study location near you, please visit www.athiraclinicaltrials.com

***The safety and efficacy of ATH-1017 for the treatment of mild to moderate Alzheimer's has not been previously established**